TWD 70.8
(0.28%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -84.1 Million TWD | 7.73% |
2022 | -91.15 Million TWD | -5.54% |
2021 | -86.37 Million TWD | 20.91% |
2020 | -109.2 Million TWD | -8.19% |
2019 | -100.93 Million TWD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | -25.95 Million TWD | 17.63% |
2024 Q1 | -31.51 Million TWD | -23.38% |
2023 Q3 | -25.54 Million TWD | -64.1% |
2023 FY | -84.1 Million TWD | 7.73% |
2023 Q2 | -15.56 Million TWD | 10.88% |
2023 Q1 | -17.46 Million TWD | 32.34% |
2023 Q4 | -25.54 Million TWD | 0.0% |
2022 FY | -91.15 Million TWD | -5.54% |
2022 Q4 | -25.81 Million TWD | 0.0% |
2021 FY | -86.37 Million TWD | 20.91% |
2020 FY | -109.2 Million TWD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Apex Biotechnology Corp. | 115.78 Million TWD | 172.643% |
Sinphar Pharmaceutical Co.,Ltd. | 375.17 Million TWD | 122.419% |
Panion & Bf Biotech Inc. | 77.21 Million TWD | 208.921% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 264.9 Million TWD | 131.75% |
GenMont Biotech Incorporation | 32.99 Million TWD | 354.942% |
Abnova (Taiwan) Corporation | 43.67 Million TWD | 292.564% |
Adimmune Corporation | -639.89 Million TWD | 86.856% |
Tanvex BioPharma, Inc. | -2.13 Billion TWD | 96.064% |
Polaris Group | -1.57 Billion TWD | 94.666% |
Energenesis Biomedical CO.,LTD. | -260.38 Million TWD | 67.698% |
PELL Bio-Med Technology Co. Ltd. | -398.75 Million TWD | 78.907% |